Vudalimab

Tax included
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
MedChemExpress 
HY-P99166

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1; CTLA-4; Interleukin Related
Application
COVID-19-immunoregulation
CAS
2329669-72-7